Across TCGA pan-cancer cohorts, LINC01602 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of LINC01602’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where LINC01602 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01602 is over-expressed in tumor, although a few such as LUAD and THCA show the opposite, repressed pattern.
COAD, HNSC, and LUAD are the cancer types where LINC01602 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01602 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.